Hemodynamic Instability During Liver Transplantation in Patients With End-stage Liver Disease: A Consensus Document from ILTS, LICAGE, and SATA.
Journal
Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144
Informations de publication
Date de publication:
01 10 2021
01 10 2021
Historique:
pubmed:
4
2
2021
medline:
3
11
2021
entrez:
3
2
2021
Statut:
ppublish
Résumé
Hemodynamic instability (HDI) during liver transplantation (LT) can be difficult to manage and increases postoperative morbidity and mortality. In addition to surgical causes of HDI, patient- and graft-related factors are also important. Nitric oxide-mediated vasodilatation is a common denominator associated with end-stage liver disease related to HDI. Despite intense investigation, optimal management strategies remain elusive. In this consensus article, experts from the International Liver Transplantation Society, the Liver Intensive Care Group of Europe, and the Society for the Advancement of Transplant Anesthesia performed a rigorous review of the most current literature regarding the epidemiology, causes, and management of HDI during LT. Special attention has been paid to unique LT-associated conditions including the causes and management of vasoplegic syndrome, cardiomyopathies, LT-related arrhythmias, right and left ventricular dysfunction, and the specifics of medical and fluid management in end-stage liver disease as well as problems specifically related to portal circulation. When possible, management recommendations are made.
Identifiants
pubmed: 33534523
doi: 10.1097/TP.0000000000003642
pii: 00007890-202110000-00015
doi:
Types de publication
Journal Article
Practice Guideline
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2184-2200Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
F.H.S. received honoraria from the speaker’s offices of CSL Behring, Werfen GmbH, Biotest, and Merz Pharmaceuticals. The other authors declare no conflicts of interest.
Références
Shekelle PG, Woolf SH, Eccles M, et al. Clinical guidelines: developing guidelines. BMJ. 1999;318:593–596.
Calne RY, Smith DP, McMaster P, et al. Use of partial cardiopulmonary bypass during the anhepatic phase of orthotopic liver grafting. Lancet. 1979;2:612–614.
Shaw BW Jr, Martin DJ, Marquez JM, et al. Venous bypass in clinical liver transplantation. Ann Surg. 1984;200:524–534.
Mandell MS, Katz JJ, Wachs M, et al. Circulatory pathophysiology and options in hemodynamic management during adult liver transplantation. Liver Transpl Surg. 1997;3:379–387.
Veroli P, el Hage C, Ecoffey C. Does adult liver transplantation without venovenous bypass result in renal failure? Anesth Analg. 1992;75:489–494.
Schwarz B, Pomaroli A, Hoermann C, et al. Liver transplantation without venovenous bypass: morbidity and mortality in patients with greater than 50% reduction in cardiac output after vena cava clamping. J Cardiothorac Vasc Anesth. 2001;15:460–462.
Gurusamy KS, Koti R, Pamecha V, et al. Veno-venous bypass versus none for liver transplantation. Cochrane Database Syst Rev 2011:CD007712.
Figueras J, Llado L, Ramos E, et al. Temporary portocaval shunt during liver transplantation with vena cava preservation. Results of a prospective randomized study. Liver Transpl. 2001;7:904–911.
Newby DE, Hayes PC. Hyperdynamic circulation in liver cirrhosis: not peripheral vasodilatation but ‘splanchnic steal’. QJM. 2002;95:827–830.
Willuweit K, Bezinover D, Herzer K, et al. Efficacy of IgM-enriched immunoglobulin for vasopressor-resistant vasoplegic shock after liver transplantation. Transplantation. 2019;103:381–386.
Bezinover D, McQuillan P, Rossignol J, et al. Vasoplegic shock during liver transplantation: is the preoperative cGMP plasma level a potential predictor of hemodynamic instability? Med Sci Monit. 2010;16:CS114–CS117.
Zhao J, Li N, Sun H, et al. The prevalence of coronary artery disease in patients with liver cirrhosis: a meta-analysis. Eur J Gastroenterol Hepatol. 2018;30:118–120.
Carey WD, Dumot JA, Pimentel RR, et al. The prevalence of coronary artery disease in liver transplant candidates over age 50. Transplantation. 1995;59:859–864.
Arslan U, Türkoğlu S, Balcioğlu S, et al. Association between nonalcoholic fatty liver disease and coronary artery disease. Coron Artery Dis. 2007;18:433–436.
Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84.
Plotkin JS, Scott VL, Pinna A, et al. Morbidity and mortality in patients with coronary artery disease undergoing orthotopic liver transplantation. Liver Transpl Surg. 1996;2:426–30.
Wray C, Scovotti JC, Tobis J, et al. Liver transplantation outcome in patients with angiographically proven coronary artery disease: a multi-institutional study. Am J Transplant. 2013;13:184–191.
Kuo PC, Plotkin JS, Gaine S, et al. Portopulmonary hypertension and the liver transplant candidate. Transplantation. 1999;67:1087–1093.
DuBrock HM, Channick RN, Krowka MJ. What’s new in the treatment of portopulmonary hypertension? Expert Rev Gastroenterol Hepatol. 2015;9:983–992.
Martin P, DiMartini A, Feng S, et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014;59:1144–1165.
Peiris P, Pai SL, Aniskevich S III, et al. Intracardiac thrombosis during liver transplant: a 17-year single-institution study. Liver Transpl. 2015;21:1280–1285.
Cherian TP, Chiu K, Gunson B, et al. Pulmonary thromboembolism in liver transplantation: a retrospective review of the first 25 years. Transpl Int. 2010;23:1113–1119.
Xia VW, Ho JK, Nourmand H, et al. Incidental intracardiac thromboemboli during liver transplantation: incidence, risk factors, and management. Liver Transpl. 2010;16:1421–1427.
Lerner AB, Sundar E, Mahmood F, et al. Four cases of cardiopulmonary thromboembolism during liver transplantation without the use of antifibrinolytic drugs. Anesth Analg. 2005;101:1608–1612.
Warnaar N, Molenaar IQ, Colquhoun SD, et al. Intraoperative pulmonary embolism and intracardiac thrombosis complicating liver transplantation: a systematic review. J Thromb Haemost. 2008;6:297–302.
Ellis JE, Lichtor JL, Feinstein SB, et al. Right heart dysfunction, pulmonary embolism, and paradoxical embolization during liver transplantation. A transesophageal two-dimensional echocardiographic study. Anesth Analg. 1989;68:777–782.
Sakai T, Matsusaki T, Dai F, et al. Pulmonary thromboembolism during adult liver transplantation: incidence, clinical presentation, outcome, risk factors, and diagnostic predictors. Br J Anaesth. 2012;108:469–477.
Xu J, Hong JC, Busuttil RW. Cardiac tamponade following liver transplantation after intrapericardial control of the suprahepatic vena cava. Liver Transpl. 2015;21:339–343.
Kim J, Fons RA, Scott JP, et al. Transabdominal intrapericardial approach in liver transplantation for unresectable primary hepatic functioning paraganglioma with invasion into hepatic veins and suprahepatic vena cava: a surgical and anesthesia management challenge. Transplant Proc. 2018;50:2630–2635.
Shchukin D, Lesovoy V, Garagatiy I, et al. Surgical approaches to supradiaphragmatic segment of IVC and right atrium through abdominal cavity during intravenous tumor thrombus removal. Adv Urol. 2014;2014:924269.
Bernardi M, Calandra S, Colantoni A, et al. Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology. 1998;27:28–34.
Kosar F, Ates F, Sahin I, et al. QT interval analysis in patients with chronic liver disease: a prospective study. Angiology. 2007;58:218–224.
Mozos I, Costea C, Serban C, et al. Factors associated with a prolonged QT interval in liver cirrhosis patients. J Electrocardiol. 2011;44:105–108.
Genovesi S, Prata Pizzala DM, Pozzi M, et al. QT interval prolongation and decreased heart rate variability in cirrhotic patients: relevance of hepatic venous pressure gradient and serum calcium. Clin Sci (Lond). 2009;116:851–859.
Oliver MI, Miralles R, Rubíes-Prat J, et al. Autonomic dysfunction in patients with non-alcoholic chronic liver disease. J Hepatol. 1997;26:1242–1248.
Fleckenstein JF, Frank Sm, Thuluvath PJ. Presence of autonomic neuropathy is a poor prognostic indicator in patients with advanced liver disease. Hepatology. 1996;23:471–475.
Kempler P, Szalay F, Váradi A, et al. Prolongation of the QTc-interval reflects the severity of autonomic neuropathy in primary biliary cirrhosis and in other non-alcoholic liver diseases. Z Gastroenterol. 1993;31(suppl 2):96–98.
Hung CS, Tseng PH, Tu CH, et al. Nonalcoholic fatty liver disease is associated with QT prolongation in the general population. J Am Heart Assoc. 2015;4:e001820.
Ballestri S, Lonardo A, Bonapace S, et al. Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:1724–1745.
Liu YC, Hung CS, Wu YW, et al. Influence of non-alcoholic fatty liver disease on autonomic changes evaluated by the time domain, frequency domain, and symbolic dynamics of heart rate variability. PLoS One. 2013;8:e61803.
Bernardi M. Cirrhotic cardiomyopathy. Clin Liver Dis (Hoboken). 2013;2:99–101.
Lyssy LA, Soos MP. Cirrhotic Cardiomyopathy. StatPearls Publishing; 2020.
Day CP, James OF, Butler TJ, et al. QT prolongation and sudden cardiac death in patients with alcoholic liver disease. Lancet. 1993;341:1423–1428.
Finucci G, Lunardi F, Sacerdoti D, et al. Q-T interval prolongation in liver cirrhosis. Reversibility after orthotopic liver transplantation. Jpn Heart J. 1998;39:321–329.
Luca C. Electrophysiological properties of right heart and atrioventricular conducting system in patients with alcoholic cardiomyopathy. Br Heart J. 1979;42:274–281.
Ward CA, Ma Z, Lee SS, et al. Potassium currents in atrial and ventricular myocytes from a rat model of cirrhosis. Am J Physiol. 1997;273(Pt 1):G537–G544.
Pochmalicki G, Genest M, Jibril H. Late ventricular potentials and heavy drinking. Heart. 1997;78:163–165.
Khan Q, Ismail M, Haider I, et al. Prevalence of the risk factors for QT prolongation and associated drug-drug interactions in a cohort of medical inpatients. J Formos Med Assoc. 2019;118(Pt 1):109–115.
Letsas KP, Efremidis M, Filippatos GS, et al. Drug-induced long QT syndrome. Hellenic J Cardiol. 2007;48:296–299.
Hodak SP, Moubarak JB, Rodriguez I, et al. QT prolongation and near fatal cardiac arrhythmia after intravenous tacrolimus administration: a case report. Transplantation. 1998;66:535–537.
Chalasani N, Gorski JC, Patel NH, et al. Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts. Hepatology. 2001;34:1103–1108.
Gundling F, Schmidtler F, Zelihic E, et al. Frequency of cardiac arrhythmia in patients with liver cirrhoses and evaluation of associated factors. Z Gastroenterol. 2012;50:1149–1155.
Mozos I. Arrhythmia risk in liver cirrhosis. World J Hepatol. 2015;7:662–672.
Huang WA, Dunipace EA, Sorg JM, et al. Liver disease as a predictor of new-onset atrial fibrillation. J Am Heart Assoc. 2018;7:e008703.
Chokesuwattanaskul R, Thongprayoon C, Bathini T, et al. Liver transplantation and atrial fibrillation: a meta-analysis. World J Hepatol. 2018;10:761–771.
Yap YG. Inflammation and atrial fibrillation: cause or para-phenomenon? Europace. 2009;11:980–981.
Prakash K, Karna ST, Pandey CK. Atrial fibrillation during anhepatic phase liver transplantation: now what? J Anaesthesiol Clin Pharmacol. 2019;35:269–271.
Park J, Lee M, Kim J, et al. Intraoperative management to prevent cardiac collapse in a patient with a recurrent, large-volume pericardial effusion and paroxysmal atrial fibrillation during liver transplantation: a case report. Transplant Proc. 2019;51:568–574.
Molinari M, Sood P, Samra PB, et al. Atrial fibrillation in renal or liver transplant recipients: a systematic review and meta-analysis. Transplant Rev (Orlando). 2019;33:29–38.
Aggarwal S, Kang Y, Freeman JA, et al. Postreperfusion syndrome: cardiovascular collapse following hepatic reperfusion during liver transplantation. Transplant Proc. 1987;19:54–55.
Hilmi I, Horton CN, Planinsic RM, et al. The impact of postreperfusion syndrome on short-term patient and liver allograft outcome in patients undergoing orthotopic liver transplantation. Liver Transpl. 2008;14:504–508.
Daniela K, Michael Z, Florian I, et al. Influence of retrograde flushing via the caval vein on the post-reperfusion syndrome in liver transplantation. Clin Transplant. 2004;18:638–641.
Ryu HG, Jung CW, Lee CS, et al. Nafamostat mesilate attenuates postreperfusion syndrome during liver transplantation. Am J Transplant. 2011;11:977–983.
Shillcutt SK, Ringenberg KJ, Chacon MM, et al. Liver transplantation: intraoperative transesophageal echocardiography findings and relationship to major postoperative adverse cardiac events. J Cardiothorac Vasc Anesth. 2016;30:107–114.
Kalisvaart M, de Haan JE, Hesselink DA, et al. The postreperfusion syndrome is associated with acute kidney injury following donation after brain death liver transplantation. Transpl Int. 2017;30:660–669.
Bezinover D, Kadry Z, McCullough P, et al. Release of cytokines and hemodynamic instability during the reperfusion of a liver graft. Liver Transpl. 2011;17:324–330.
Bellamy MC, Gedney JA, Buglass H, et al.; Leeds Liver Group. Complement membrane attack complex and hemodynamic changes during human orthotopic liver transplantation. Liver Transpl. 2004;10:273–278.
Bellamy MC, Galley HF, Webster NR. Changes in inflammatory mediators during orthotopic liver transplantation. Br J Anaesth. 1997;79:338–341.
Jun IG, Kwon HM, Jung KW, et al. The impact of postreperfusion syndrome on acute kidney injury in living donor liver transplantation: a propensity score analysis. Anesth Analg. 2018;127:369–378.
Xu ZD, Xu HT, Yuan HB, et al. Postreperfusion syndrome during orthotopic liver transplantation: a single-center experience. Hepatobiliary Pancreat Dis Int. 2012;11:34–39.
Paugam-Burtz C, Kavafyan J, Merckx P, et al. Postreperfusion syndrome during liver transplantation for cirrhosis: outcome and predictors. Liver Transpl. 2009;15:522–529.
Roller J, Glanemann M. Keep the pressure! Correlation of hemodynamic instability after reperfusion and severity of acute kidney injury following liver transplantation. Transpl Int. 2017;30:658–659.
Zerillo J, Hill B, Kim S, et al. Use, training, and opinions about effectiveness of transesophageal echocardiography in adult liver transplantation among anesthesiologists in the United States. Semin Cardiothorac Vasc Anesth. 2018;22:137–145.
Schumann R, Mandell MS, Mercaldo N, et al. Anesthesia for liver transplantation in United States academic centers: intraoperative practice. J Clin Anesth. 2013;25:542–550.
Burtenshaw AJ, Isaac JL. The role of trans-oesophageal echocardiography for perioperative cardiovascular monitoring during orthotopic liver transplantation. Liver Transpl. 2006;12:1577–1583.
Lu SY, Matsusaki T, Abuelkasem E, et al. Complications related to invasive hemodynamic monitors during adult liver transplantation. Clin Transplant. 2013;27:823–828.
Pai SL, Aniskevich S III, Feinglass NG, et al. Complications related to intraoperative transesophageal echocardiography in liver transplantation. Springerplus. 2015;4:480.
Burger-Klepp U, Karatosic R, Thum M, et al. Transesophageal echocardiography during orthotopic liver transplantation in patients with esophagoastric varices. Transplantation. 2012;94:192–196.
Krowka MJ, Fallon MB, Kawut SM, et al. International Liver Transplant Society Practice Guidelines: diagnosis and management of hepatopulmonary syndrome and portopulmonary hypertension. Transplantation. 2016;100:1440–1452.
Auxiliadora-Martins M, Apinagés Dos Santos E, Adans Wenzinger D, et al. Perforation of the right ventricle induced by pulmonary artery catheter at induction of anesthesia for the surgery for liver transplantation: a case report and reviewed of literature. Case Rep Med. 2009;2009:650982.
Evans DC, Doraiswamy VA, Prosciak MP, et al. Complications associated with pulmonary artery catheters: a comprehensive clinical review. Scand J Surg. 2009;98:199–208.
Shih BF, Huang PH, Yu HP, et al. Cardiac output assessed by the fourth-generation arterial waveform analysis system is unreliable in liver transplant recipients. Transplant Proc. 2016;48:1170–1175.
Suparschi V, Le Bihan E, Toussaint A, et al. Noninvasive assessment of Cardiac Index using impedance cardiography during liver transplantation surgery: a comparison with pulmonary artery thermodilution. Minerva Anestesiol. 2019;85:28–33.
Biancofiore G, Critchley LA, Lee A, et al. Evaluation of an uncalibrated arterial pulse contour cardiac output monitoring system in cirrhotic patients undergoing liver surgery. Br J Anaesth. 2009;102:47–54.
Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43:304–377.
Futier E, Lefrant JY, Guinot PG, et al.; INPRESS Study Group. Effect of individualized vs standard blood pressure management strategies on postoperative organ dysfunction among high-risk patients undergoing major surgery: a randomized clinical trial. JAMA. 2017;318:1346–1357
Avni T, Lador A, Lev S, et al. Vasopressors for the treatment of septic shock: systematic review and meta-analysis. PLoS One. 2015;10:e0129305.
Gamper G, Havel C, Arrich J, et al. Vasopressors for hypotensive shock. Cochrane Database Syst Rev. 2016;2:CD003709.
Myburgh JA, Higgins A, Jovanovska A, et al.; CAT Study investigators. A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Med. 2008;34:2226–2234.
Wagener G, Kovalevskaya G, Minhaz M, et al. Vasopressin deficiency and vasodilatory state in end-stage liver disease. J Cardiothorac Vasc Anesth. 2011;25:665–670.
Keegan MT, Gali B, Brown DR, et al. Serum vasopressin concentrations during orthotopic liver transplantation. Transplant Proc. 2010;42:2594–2598.
Russell JA, Walley KR, Singer J, et al.; VASST Investigators. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358:877–887.
Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med. 2001;345:588–595.
Palanisamy AP, Nadig SN, Chedister GR, et al. Use of intra-aortic counterpulsation in cardiogenic shock post-liver transplantation. Clin Transplant. 2017;31:1–4.
Sharma S, Karamchandani K, Wilson R, et al. Acute heart failure after orthotopic liver transplantation: a case series from one center. BMC Anesthesiol. 2018;18:102.
Tejani M, Yi SY, Eudailey KW, et al. Extracorporeal membrane oxygenation as a rescue device for postreperfusion cardiac arrest during liver transplantation. Liver Transpl. 2015;21:410–414.
Axelrod D, Koffron A, Dewolf A, et al. Safety and efficacy of combined orthotopic liver transplantation and coronary artery bypass grafting. Liver Transpl. 2004;10:1386–1390.
Kim IH, Kim GS, Ko JS, et al. Combined off-pump coronary artery bypass grafting and living donor liver transplantation: a case report. Korean J Anesthesiol. 2009;57:108–112.
Khan TA, Schnickel G, Ross D, et al. A prospective, randomized, crossover pilot study of inhaled nitric oxide versus inhaled prostacyclin in heart transplant and lung transplant recipients. J Thorac Cardiovasc Surg. 2009;138:1417–1424.
AbuHalimeh B, Krowka MJ, Tonelli AR. Treatment barriers in portopulmonary hypertension. Hepatology. 2019;69:431–443.
Lamarche Y, Malo O, Thorin E, et al. Inhaled but not intravenous milrinone prevents pulmonary endothelial dysfunction after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 2005;130:83–92.
Koh H, Ahn S, Lee J. What do we take consideration in the patient who has an unpredicted severe portopulmonary hypertension in liver transplantation?: a case report. Korean J Anesthesiol. 2015;68:83–86.
Vater Y, Martay K, Dembo G, et al. Intraoperative epoprostenol and nitric oxide for severe pulmonary hypertension during orthotopic liver transplantation: a case report and review of the literature. Med Sci Monit. 2006;12:CS115–CS118.
Ramsay MA, Spikes C, East CA, et al. The perioperative management of portopulmonary hypertension with nitric oxide and epoprostenol. Anesthesiology. 1999;90:299–301.
Fukazawa K, Poliac LC, Pretto EA. Rapid assessment and safe management of severe pulmonary hypertension with milrinone during orthotopic liver transplantation. Clin Transplant. 2010;24:515–519.
Martucci G, Burgio G, Lullo F, et al. Veno-arterial extracorporeal membrane oxygenation as an intraoperative rescue option in case of portopulmonary hypertension recognized during liver transplantation. Minerva Anestesiol. 2017;83:1336–1337.
Chan-Dominy AC, Rahiman SN, Anders M, et al. Extracorporeal membrane oxygenation and severe portopulmonary hypertension following liver transplantation: brief report. Int J Artif Organs. 2015;38:337–342.
Stratta C, Lavezzo B, Ballaris MA, et al. Extracorporeal membrane oxygenation rescue therapy in a case of portopulmonary hypertension during liver transplantation: a case report. Transplant Proc. 2013;45:2774–2775.
Boone JD, Sherwani SS, Herborn JC, et al. The successful use of low-dose recombinant tissue plasminogen activator for treatment of intracardiac/pulmonary thrombosis during liver transplantation. Anesth Analg. 2011;112:319–321.
Mandell D, Planinsic R, Melean F, et al. Critical importance of low-dose tissue plasminogen activator policy for treating intraoperative pulmonary thromboembolism during liver transplantation. Semin Cardiothorac Vasc Anesth. 2018;22:376–382.
Protin C, Bezinover D, Kadry Z, et al. Emergent management of intracardiac thrombosis during liver transplantation. Case Rep Transplant. 2016;2016:6268370.
Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2016;67:e27–e115.
Link MS, Berkow LC, Kudenchuk PJ, et al. Part 7: Adult advanced cardiovascular life support: 2015 American Heart Association Guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2015;132:S444–S464.
Panchal AR, Berg KM, Kudenchuk PJ, et al. 2018 American Heart Association focused update on advanced cardiovascular life support use of antiarrhythmic drugs during and immediately after cardiac arrest: an update to the American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2018;138:e740–e749.
January CT, Wann LS, Alpert JS, et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1–76.
von Vital JM, Karachristos A, Singhal A, et al. Acute amiodarone hepatotoxicity after liver transplantation. Transplantation. 2011;91:e62–e64.
Diab OA, Kamel J, Abd-Elhamid AA. Predictors of intravenous amiodarone induced liver injury. Egypt Heart J. 2017;69:45–54.
Siniscalchi A, Gamberini L, Laici C, et al. Post reperfusion syndrome during liver transplantation: from pathophysiology to therapy and preventive strategies. World J Gastroenterol. 2016;22:1551–1569.
Fukazawa K, Yamada Y, Gologorsky E, et al. Hemodynamic recovery following postreperfusion syndrome in liver transplantation. J Cardiothorac Vasc Anesth. 2014;28:994–1002.
Ryu HG, Jung CW, Lee HC, et al. Epinephrine and phenylephrine pretreatments for preventing postreperfusion syndrome during adult liver transplantation. Liver Transpl. 2012;18:1430–1439.
Chung IS, Jee HS, Han S, et al. Effect of prereperfusion ephedrine on postreperfusion syndrome and graft function in living donor liver transplantation. Transplant Proc. 2017;49:1815–1819.
NA F, WS M. Goal directed preemptive ephedrine attenuates the reperfusion syndrome during adult living donor liver transplantation. Egyptian J Anaesth. 2014;30:187–95.
O’Brien A. Con: the unclear benefit of albumin. Liver Transpl. 2019;25:135–139.
Garcia-Martinez R, Caraceni P, Bernardi M, et al. Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology. 2013;58:1836–1846.
Huang CJ, Cheng KW, Chen CL, et al. Clinical beneficial effects of using crystalloid only in recipients of living donor liver transplantation. Int J Environ Res Public Health. 2017;14:1418.
Amouzandeh M, Nowak G, Januszkiewicz A, et al. Albumin mass balance and kinetics in liver transplantation. Crit Care. 2018;22:152.
Lee EM, Kang JK, Yun SC, et al. Risk factors for central pontine and extrapontine myelinolysis following orthotopic liver transplantation. Eur Neurol. 2009;62:362–368.
George JC, Zafar W, Bucaloiu ID, et al. Risk factors and outcomes of rapid correction of severe hyponatremia. Clin J Am Soc Nephrol. 2018;13:984–992.
Bronster DJ, Emre S, Boccagni P, et al. Central nervous system complications in liver transplant recipients—incidence, timing, and long-term follow-up. Clin Transplant. 2000;14:1–7.
Yu J, Zheng SS, Liang TB, et al. Possible causes of central pontine myelinolysis after liver transplantation. World J Gastroenterol. 2004;10:2540–2543.
Modi MP, Vora KS, Parikh GP, et al. A comparative study of impact of infusion of Ringer’s Lactate solution versus normal saline on acid-base balance and serum electrolytes during live related renal transplantation. Saudi J Kidney Dis Transpl. 2012;23:135–137.
Kim SY, Huh KH, Lee JR, et al. Comparison of the effects of normal saline versus Plasmalyte on acid-base balance during living donor kidney transplantation using the Stewart and base excess methods. Transplant Proc. 2013;45:2191–2196.
Adwaney A, Randall DW, Blunden MJ, et al. Perioperative Plasma-Lyte use reduces the incidence of renal replacement therapy and hyperkalaemia following renal transplantation when compared with 0.9% saline: a retrospective cohort study. Clin Kidney J. 2017;10:838–844.
Yoshino O, Perini MV, Christophi C, et al. Perioperative fluid management in major hepatic resection: an integrative review. Hepatobiliary Pancreat Dis Int. 2017;16:458–469.
Mizunoya K, Fujii T, Yamamoto M, et al. Two-stage goal-directed therapy protocol for non-donor open hepatectomy: an interventional before-after study. J Anesth. 2019;33:656–664.
Kravetz D, Sikuler E, Groszmann RJ. Splanchnic and systemic hemodynamics in portal hypertensive rats during hemorrhage and blood volume restitution. Gastroenterology. 1986;90:1232–1240.
Castañeda B, Morales J, Lionetti R, et al. Effects of blood volume restitution following a portal hypertensive-related bleeding in anesthetized cirrhotic rats. Hepatology. 2001;33:821–825.
Giannini EG, Stravitz RT, Caldwell SH. Correction of hemostatic abnormalities and portal pressure variations in patients with cirrhosis. Hepatology. 2014;60:1442.
Zimmon DS, Kessler RE. The portal pressure-blood volume relationship in cirrhosis. Gut. 1974;15:99–101.
Holland LL, Brooks JP. Toward rational fresh frozen plasma transfusion: the effect of plasma transfusion on coagulation test results. Am J Clin Pathol. 2006;126:133–139.
Brand A. Immunological aspects of blood transfusions. Transpl Immunol. 2002;10:183–190.
Spiess BD. Risks of transfusion: outcome focus. Transfusion. 2004;44(suppl 12):4S–14S.
de Boer MT, Christensen MC, Asmussen M, et al. The impact of intraoperative transfusion of platelets and red blood cells on survival after liver transplantation. Anesth Analg. 2008;106:32–44.
Hendriks HG, van der Meer J, de Wolf JT, et al. Intraoperative blood transfusion requirement is the main determinant of early surgical re-intervention after orthotopic liver transplantation. Transpl Int. 2005;17:673–679.
Carrier FM, Chassé M, Wang HT, et al. Restrictive fluid management strategies and outcomes in liver transplantation: a systematic review. Can J Anaesth. 2020;67:109–127.
Carrier FM, Chassé M, Sylvestre MP, et al. Effects of intraoperative fluid balance during liver transplantation on postoperative acute kidney injury: an observational cohort study. Transplantation. 2020;104:1419–1428.
Westerkamp AC, Lisman T, Porte RJ. How to minimize blood loss during liver surgery in patients with cirrhosis. HPB (Oxford). 2009;11:453–458.
Saner FH, Abeysundara L, Hartmann M, et al. Rational approach to transfusion in liver transplantation. Minerva Anestesiol. 2018;84:378–388.
Fayed NA, Yassen KA, Abdulla AR. Comparison between 2 strategies of fluid management on blood loss and transfusion requirements during liver transplantation. J Cardiothorac Vasc Anesth. 2017;31:1741–1750.
Wang SC, Teng WN, Chang KY, et al. Fluid management guided by stroke volume variation failed to decrease the incidence of acute kidney injury, 30-day mortality, and 1-year survival in living donor liver transplant recipients. J Chin Med Assoc. 2012;75:654–659.
Lekerika N, Gutiérrez Rico RM, Arco Vázquez J, et al. Predicting fluid responsiveness in patients undergoing orthotopic liver transplantation: effects on intraoperative blood transfusion and postoperative complications. Transplant Proc. 2014;46:3087–3091.
Feng ZY, Xu X, Zhu SM, et al. Effects of low central venous pressure during preanhepatic phase on blood loss and liver and renal function in liver transplantation. World J Surg. 2010;34:1864–1873.
Baker L, Bennett S, Rekman J, et al. Hypovolemic phlebotomy in liver surgery is associated with decreased red blood cell transfusion. HPB (Oxford). 2019;21:757–764.
Massicotte L, Denault AY, Beaulieu D, et al. Transfusion rate for 500 consecutive liver transplantations: experience of one liver transplantation center. Transplantation. 2012;93:1276–1281.
De Pietri L, Mocchegiani F, Leuzzi C, et al. Transoesophageal echocardiography during liver transplantation. World J Hepatol. 2015;7:2432–2448.
Vetrugno L, Barbariol F, Baccarani U, et al. Transesophageal echocardiography in orthotopic liver transplantation: a comprehensive intraoperative monitoring tool. Crit Ultrasound J. 2017;9:15.
European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu ; European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69:406–460.
Cleland S, Corredor C, Ye JJ, et al. Massive haemorrhage in liver transplantation: consequences, prediction and management. World J Transplant. 2016;6:291–305.
Chidananda Swamy M. Blood transfusion practices in liver transplantation. Indian J Anaesth. 2014;58:647–651.
Agarwal S, Senzolo M, Melikian C, et al. The prevalence of a heparin-like effect shown on the thromboelastograph in patients undergoing liver transplantation. Liver Transpl. 2008;14:855–860.
Senzolo M, Coppell J, Cholongitas E, et al. The effects of glycosaminoglycans on coagulation: a thromboelastographic study. Blood Coagul Fibrinolysis. 2007;18:227–236.
Verstraete M. Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins. Drugs. 1990;40:498–530.
Zardi EM, Abbate A, Zardi DM, et al. Cirrhotic cardiomyopathy. J Am Coll Cardiol. 2010;56:539–549.
Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29:277–314.
Izzy M, VanWagner LB, Lin G, et al.; Cirrhotic Cardiomyopathy Consortium. Redefining cirrhotic cardiomyopathy for the modern era. Hepatology. 2020;71:334–345.
Gassanov N, Caglayan E, Semmo N, et al. Cirrhotic cardiomyopathy: a cardiologist’s perspective. World J Gastroenterol. 2014;20:15492–15498.
Rahman S, Mallett SV. Cirrhotic cardiomyopathy: implications for the perioperative management of liver transplant patients. World J Hepatol. 2015;7:507–520.
Mocarzel LO, Bicca J, Jarske L, et al. Cirrhotic cardiomyopathy: another case of a successful approach to treatment of hepatorenal syndrome. Case Rep Gastroenterol. 2016;10:531–537.
Ruiz-del-Árbol L, Serradilla R. Cirrhotic cardiomyopathy. World J Gastroenterol. 2015;21:11502–11521.
Baik SK, Fouad TR, Lee SS. Cirrhotic cardiomyopathy. Orphanet J Rare Dis. 2007;2:15.
Al Hamoudi W, Lee SS. Cirrhotic cardiomyopathy. Ann Hepatol. 2006;5:132–139.
Milani A, Zaccaria R, Bombardieri G, et al. Cirrhotic cardiomyopathy. Dig Liver Dis. 2007;39:507–515.
Møller S, Henriksen JH. Cardiovascular complications of cirrhosis. Gut. 2008;57:268–278.
Møller S, Henriksen JH. Cirrhotic cardiomyopathy. J Hepatol. 2010;53:179–190.
Alqahtani SA, Fouad TR, Lee SS. Cirrhotic cardiomyopathy. Semin Liver Dis. 2008;28:59–69.
Torregrosa M, Aguadé S, Dos L, et al. Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol. 2005;42:68–74.
Laonigro I, Correale M, Di Biase M, et al. Alcohol abuse and heart failure. Eur J Heart Fail. 2009;11:453–462.
Roger VL. Epidemiology of heart failure. Circ Res. 2013;113:646–659.
Tiukinhoy-Laing SD, Rossi JS, Bayram M, et al. Cardiac hemodynamic and coronary angiographic characteristics of patients being evaluated for liver transplantation. Am J Cardiol. 2006;98:178–181.
Gologorsky E, Pretto EA Jr, Fukazawa K. Coronary artery disease and its risk factors in patients presenting for liver transplantation. J Clin Anesth. 2013;25:618–623.
Merlo M, Cannatà A, Gobbo M, et al. Evolving concepts in dilated cardiomyopathy. Eur J Heart Fail. 2018;20:228–239.
Weintraub RG, Semsarian C, Macdonald P. Dilated cardiomyopathy. Lancet. 2017;390:400–414.
Hensley N, Dietrich J, Nyhan D, et al. Hypertrophic cardiomyopathy: a review. Anesth Analg. 2015;120:554–569.
Maraj S, Jacobs LE, Maraj R, et al. Inducible left ventricular outflow tract gradient during dobutamine stress echocardiography: an association with intraoperative hypotension but not a contraindication to liver transplantation. Echocardiography. 2004;21:681–685.
Cywinski JB, Argalious M, Marks TN, et al. Dynamic left ventricular outflow tract obstruction in an orthotopic liver transplant recipient. Liver Transpl. 2005;11:692–695.
Essandoh M, Otey AJ, Dalia A, et al. Refractory hypotension after liver allograft reperfusion: a case of dynamic left ventricular outflow tract obstruction. Front Med (Lausanne). 2016;3:3.
Harley ID, Jones EF, Liu G, et al. Orthotopic liver transplantation in two patients with hypertrophic obstructive cardiomyopathy. Br J Anaesth. 1996;77:675–677.
Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003;348:295–303.
Pai SL, Aniskevich S III, Logvinov II, et al. Hypertrophic cardiomyopathy in liver transplantation patients. Transplant Proc. 2018;50:1466–1469.
Muchtar E, Blauwet LA, Gertz MA. Restrictive cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res. 2017;121:819–837.
Díez-López C, Comín-Colet J, González-Costello J. Iron overload cardiomyopathy: from diagnosis to management. Curr Opin Cardiol. 2018;33:334–340.
Aronow WS, Meister L, Kent JR. Atrioventricular block in familial hemochromatosis treated by permanent synchronous pacemaker. Arch Intern Med. 1969;123:433–435.
Benson MD. Liver transplantation and transthyretin amyloidosis. Muscle Nerve. 2013;47:157–162.
Siddiqi OK, Ruberg FL. Cardiac amyloidosis: an update on pathophysiology, diagnosis, and treatment. Trends Cardiovasc Med. 2018;28:10–21.
Yataco ML, Difato T, Bargehr J, et al. Reversible non-ischaemic cardiomyopathy and left ventricular dysfunction after liver transplantation: a single-centre experience. Liver Int. 2014;34:e105–e110.
Tiwari AK, D’Attellis N. Intraoperative left ventricular apical ballooning: transient Takotsubo cardiomyopathy during orthotopic liver transplantation. J Cardiothorac Vasc Anesth. 2008;22:442–445.
Eagle SS, Thompson A, Fong PP, et al. Takotsubo cardiomyopathy and coronary vasospasm during orthotopic liver transplantation: separate entities or common mechanism? J Cardiothorac Vasc Anesth. 2010;24:629–632.
Harika R, Bermas K, Hughes C, et al. Cardiac arrest after liver transplantation in a patient with Takotsubo cardiomyopathy. Br J Anaesth. 2014;112:594–595.
Thorne KD, Kerut EK, Moore CK. Apical ballooning “tako-tsubo” syndrome associated with transient left ventricular outflow tract obstruction. Echocardiography. 2007;24:770–772.
Vitin AA, Azamfirei L, Tomescu D. Perioperative stress-induced (Takotsubo) cardiomyopathy in liver transplant recipients. J Crit Care Med (Targu Mures). 2018;4:56–63.
Lentine KL, Costa SP, Weir MR, et al.; American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Peripheral Vascular Disease. Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2012;60:434–480.
Cannon RM, Hughes MG, Jones CM, et al. A review of the United States experience with combined heart-liver transplantation. Transpl Int. 2012;25:1223–1228.
Bryant R III, Rizwan R, Zafar F, et al. Contemporary outcomes of combined heart-liver transplant in patients with congenital heart disease. Transplantation. 2018;102:e67–e73.
Beal EW, Mumtaz K, Hayes D Jr, et al. Combined heart-liver transplantation: indications, outcomes and current experience. Transplant Rev (Orlando). 2016;30:261–268.
Zhao K, Mclean RC, Hoteit MA, et al. Combined heart and liver transplant: indication, patient selection, and allocation policy. Clin Liver Dis (Hoboken). 2019;13:170–175.
Al-Hamoudi WK. Cardiovascular changes in cirrhosis: pathogenesis and clinical implications. Saudi J Gastroenterol. 2010;16:145–153.
Liu H, Jayakumar S, Traboulsi M, et al. Cirrhotic cardiomyopathy: implications for liver transplantation. Liver Transpl. 2017;23:826–835.
Lee RF, Glenn TK, Lee SS. Cardiac dysfunction in cirrhosis. Best Pract Res Clin Gastroenterol. 2007;21:125–140.
Raval Z, Harinstein ME, Skaro AI, et al. Cardiovascular risk assessment of the liver transplant candidate. J Am Coll Cardiol. 2011;58:223–231.
Sharkey SW, Lesser JR, Zenovich AG, et al. Acute and reversible cardiomyopathy provoked by stress in women from the United States. Circulation. 2005;111:472–479.
Bielecka-Dabrowa A, Mikhailidis DP, Hannam S, et al. Takotsubo cardiomyopathy–the current state of knowledge. Int J Cardiol. 2010;142:120–125.
Phillips MS, Pruett TL, Berg CL, et al. Takotsubo cardiomyopathy in a liver transplant recipient: a diagnosis of exclusion? J Cardiothorac Vasc Anesth. 2009;23:268–269.
Biondi RS, Barzilai VS, Watanabe ALC, et al. Use of extracorporeal membrane oxygenation for treating acute cardiomyopathy after liver transplantation: a case report. Rev Bras Ter Intensiva. 2018;30:233–236.
Shanmugam G. Vasoplegic syndrome—the role of methylene blue. Eur J Cardiothorac Surg. 2005;28:705–710.
Gomes WJ, Carvalho AC, Palma JH, et al. Vasoplegic syndrome: a new dilemma. J Thorac Cardiovasc Surg. 1994;107:942–943.
Ozal E, Kuralay E, Yildirim V, et al. Preoperative methylene blue administration in patients at high risk for vasoplegic syndrome during cardiac surgery. Ann Thorac Surg. 2005;79:1615–1619.
Fischer GW, Levin MA. Vasoplegia during cardiac surgery: current concepts and management. Semin Thorac Cardiovasc Surg. 2010;22:140–144.
Byrne JG, Leacche M, Paul S, et al. Risk factors and outcomes for ‘vasoplegia syndrome’ following cardiac transplantation. Eur J Cardiothorac Surg. 2004;25:327–332.
Harrison P, Wendon J, Williams R. Evidence of increased guanylate cyclase activation by acetylcysteine in fulminant hepatic failure. Hepatology. 1996;23:1067–1072.
Galley HF, Coomansingh D, Webster NR, et al. Nitric oxide synthase activity is increased in relation to the severity of liver dysfunction. Clin Sci (Lond). 1998;95:355–359.
Bode C, Kugler V, Bode JC. Endotoxemia in patients with alcoholic and non-alcoholic cirrhosis and in subjects with no evidence of chronic liver disease following acute alcohol excess. J Hepatol. 1987;4:8–14.
García-Tsao G. Bacterial translocation: cause or consequence of decompensation in cirrhosis? J Hepatol. 2001;34:150–155.
Laffi G, Foschi M, Masini E, et al. Increased production of nitric oxide by neutrophils and monocytes from cirrhotic patients with ascites and hyperdynamic circulation. Hepatology. 1995;22:1666–1673.
Arroyo V, García-Martinez R, Salvatella X. Human serum albumin, systemic inflammation, and cirrhosis. J Hepatol. 2014;61:396–407.
Albillos A, Lario M, Álvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J Hepatol. 2014;61:1385–1396.
Bezinover D, Kadry Z, Uemura T, et al. Association between plasma cyclic guanosine monophosphate levels and hemodynamic instability during liver transplantation. Liver Transpl. 2013;19:191–198.
Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet. 1991;337:776–778.
Marczin N, Ryan US, Catravas JD. Methylene blue inhibits nitrovasodilator- and endothelium-derived relaxing factor-induced cyclic GMP accumulation in cultured pulmonary arterial smooth muscle cells via generation of superoxide anion. J Pharmacol Exp Ther. 1992;263:170–179.
Mayer B, Brunner F, Schmidt K. Inhibition of nitric oxide synthesis by methylene blue. Biochem Pharmacol. 1993;45:367–374.
Cao Z, Gao Y, Tao G. Vasoplegic syndrome during liver transplantation. Anesth Analg. 2009;108:1941–1943.
Cheng SS, Berman GW, Merritt GR, et al. The response to methylene blue in patients with severe hypotension during liver transplantation. J Clin Anesth. 2012;24:324–328.
Vilalva KH, Mumic FT, Silveira MRG, et al. Use of methylene blue to treat hypovolemic shock followed by ischemia-reperfusion injury in the postoperative orthotopic liver transplant patient: a case report. Exp Clin Transplant. 2018;16:511–514.
Koelzow H, Gedney JA, Baumann J, et al. The effect of methylene blue on the hemodynamic changes during ischemia reperfusion injury in orthotopic liver transplantation. Anesth Analg. 2002;94:824–829.
Evora PR, Alves Junior L, Ferreira CA, et al. Twenty years of vasoplegic syndrome treatment in heart surgery. Methylene blue revised. Rev Bras Cir Cardiovasc. 2015;30:84–92.
McCartney SL, Duce L, Ghadimi K. Intraoperative vasoplegia: methylene blue to the rescue! Curr Opin Anaesthesiol. 2018;31:43–49.
Gerth K, Ehring T, Braendle M, et al. Nitric oxide scavenging by hydroxocobalamin may account for its hemodynamic profile. Clin Toxicol (Phila). 2006;44:29–36.
Sampaio AL, Dalli J, Brancaleone V, et al. Biphasic modulation of NOS expression, protein and nitrite products by hydroxocobalamin underlies its protective effect in endotoxemic shock: downstream regulation of COX-2, IL-1β, TNF-α, IL-6, and HMGB1 expression. Mediators Inflamm. 2013;2013:741804.
Truong DH, Mihajlovic A, Gunness P, et al. Prevention of hydrogen sulfide (H2S)-induced mouse lethality and cytotoxicity by hydroxocobalamin (vitamin B(12a)). Toxicology. 2007;242:16–22.
Mustafa AK, Sikka G, Gazi SK, et al. Hydrogen sulfide as endothelium-derived hyperpolarizing factor sulfhydrates potassium channels. Circ Res. 2011;109:1259–1268.
Ebrahimkhani MR, Mani AR, Moore K. Hydrogen sulphide and the hyperdynamic circulation in cirrhosis: a hypothesis. Gut. 2005;54:1668–1671.
Cai Y, Mack A, Ladlie BL, et al. The use of intravenous hydroxocobalamin as a rescue in methylene blue-resistant vasoplegic syndrome in cardiac surgery. Ann Card Anaesth. 2017;20:462–464.
Roderique JD, VanDyck K, Holman B, et al. The use of high-dose hydroxocobalamin for vasoplegic syndrome. Ann Thorac Surg. 2014;97:1785–1786.
Boettcher BT, Woehlck HJ, Reck SE, et al. Treatment of vasoplegic syndrome with intravenous hydroxocobalamin during liver transplantation. J Cardiothorac Vasc Anesth. 2017;31:1381–1384.
An SS, Henson CP, Freundlich RE, et al. Case report of high-dose hydroxocobalamin in the treatment of vasoplegic syndrome during liver transplantation. Am J Transplant. 2018;18:1552–1555.
Feih JT, Rinka JRG, Zundel MT. Methylene blue monotherapy compared with combination therapy with hydroxocobalamin for the treatment of refractory vasoplegic syndrome: a retrospective cohort study. J Cardiothorac Vasc Anesth. 2019;33:1301–1307.
Uhl W, Nolting A, Golor G, et al. Safety of hydroxocobalamin in healthy volunteers in a randomized, placebo-controlled study. Clin Toxicol (Phila). 2006;44:17–28.
Curry SC, Connor DA, Raschke RA. Effect of the cyanide antidote hydroxocobalamin on commonly ordered serum chemistry studies. Ann Emerg Med. 1994;24:65–67.
Soares MO, Welton NJ, Harrison DA, et al. An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of information analysis. Health Technol Assess. 2012;16:1–186.
Alejandria MM, Lansang MA, Dans LF, et al. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev 2013;2013:CD001090.
Schussler O, Lantoine F, Devynck MA, et al. Human immunoglobulins inhibit thrombin-induced Ca 2+ movements and nitric oxide production in endothelial cells. J Biol Chem. 1996;271:26473–26476.
Ishikura H, Nakamura Y, Kawano Y, et al. Intravenous immunoglobulin improves sepsis-induced coagulopathy: a retrospective, single-center observational study. J Crit Care. 2015;30:579–583.
Garbett ND, Munro CS, Cole PJ. Opsonic activity of a new intravenous immunoglobulin preparation: pentaglobin compared with sandoglobulin. Clin Exp Immunol. 1989;76:8–12.
Rieben R, Roos A, Muizert Y, et al. Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation. Blood. 1999;93:942–951.
Norrby-Teglund A, Basma H, Andersson J, et al. Varying titers of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G: implications for therapeutic efficacy. Clin Infect Dis. 1998;26:631–638.
Shankar-Hari M, Spencer J, Sewell WA, et al. Bench-to-bedside review: immunoglobulin therapy for sepsis - biological plausibility from a critical care perspective. Crit Care. 2012;16:206.
Wand S, Klages M, Kirbach C, et al. IgM-enriched immunoglobulin attenuates systemic endotoxin activity in early severe sepsis: a before-after cohort study. PLoS One. 2016;11:e0160907.
Greenway CV, Stark RD. Hepatic vascular bed. Physiol Rev. 1971;51:23–65.
Jakab F, Ráth Z, Schmal F, et al. The interaction between hepatic arterial and portal venous blood flows; simultaneous measurement by transit time ultrasonic volume flowmetry. Hepatogastroenterology. 1995;42:18–21.
Lebrec D, Sogni P, Vilgrain V. Evaluation of patients with portal hypertension. Baillieres Clin Gastroenterol. 1997;11:221–241.
Gadano A, Hadengue A, Vachiery F, et al. Relationship between hepatic blood flow, liver tests, haemodynamic values and clinical characteristics in patients with chronic liver disease. J Gastroenterol Hepatol. 1997;12:167–171.
DeLeve LD. Liver sinusoidal endothelial cells in hepatic fibrosis. Hepatology. 2015;61:1740–1746.
Iwakiri Y, Shah V, Rockey DC. Vascular pathobiology in chronic liver disease and cirrhosis—current status and future directions. J Hepatol. 2014;61:912–924.
Kiszka-Kanowitz M, Henriksen JH, Møller S, et al. Blood volume distribution in patients with cirrhosis: aspects of the dual-head gamma-camera technique. J Hepatol. 2001;35:605–612.
Ozier Y, Klinck JR. Anesthetic management of hepatic transplantation. Curr Opin Anaesthesiol. 2008;21:391–400.
Henriksen JH. Volume adaptation in chronic liver disease: on the static and dynamic location of water, salt, protein and red cells in cirrhosis. Scand J Clin Lab Invest. 2004;64:523–533.
Massicotte L, Perrault MA, Denault AY, et al. Effects of phlebotomy and phenylephrine infusion on portal venous pressure and systemic hemodynamics during liver transplantation. Transplantation. 2010;89:920–927.
Bown LS, Ricksten SE, Houltz E, et al. Vasopressin-induced changes in splanchnic blood flow and hepatic and portal venous pressures in liver resection. Acta Anaesthesiol Scand. 2016;60:607–615.
Richardson PD. Physiological regulation of the hepatic circulation. Fed Proc. 1982;41:2111–2116.
Schmeisch AP, de Oliveira DS, Ide LT, et al. Zonation of the metabolic action of vasopressin in the bivascularly perfused rat liver. Regul Pept. 2005;129:233–243.
Wagener G, Gubitosa G, Renz J, et al. Vasopressin decreases portal vein pressure and flow in the native liver during liver transplantation. Liver Transpl. 2008;14:1664–1670.
Vitin AA, Martay K, Vater Y, et al. Effects of vasoactive agents on blood loss and transfusion requirements during pre-reperfusion stages of the orthotopic liver transplantation. J Anesth Clin Res. 2010;1:1–9.
Mukhtar A, Salah M, Aboulfetouh F, et al. The use of terlipressin during living donor liver transplantation: effects on systemic and splanchnic hemodynamics and renal function. Crit Care Med. 2011;39:1329–1334.
Fayed N, Refaat EK, Yassein TE, et al. Effect of perioperative terlipressin infusion on systemic, hepatic, and renal hemodynamics during living donor liver transplantation. J Crit Care. 2013;28:775–782.
Reynaert H, Geerts A. Pharmacological rationale for the use of somatostatin and analogues in portal hypertension. Aliment Pharmacol Ther. 2003;18:375–386.
D’Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis. 1999;19:475–505.
Corley DA, Cello JP, Adkisson W, et al. Octreotide for acute esophageal variceal bleeding: a meta-analysis. Gastroenterology. 2001;120:946–954.
Troisi RI, Vanlander A, Giglio MC, et al. Somatostatin as inflow modulator in liver-transplant recipients with severe portal hypertension: a randomized trial. Ann Surg. 2019;269:1025–1033.
Byram SW, Gupta RA, Ander M, et al. Effects of continuous octreotide infusion on intraoperative transfusion requirements during orthotopic liver transplantation. Transplant Proc. 2015;47:2712–2714.
Pratschke S, Rauch A, Albertsmeier M, et al. Temporary intraoperative porto-caval shunts in piggy-back liver transplantation reduce intraoperative blood loss and improve postoperative transaminases and renal function: a meta-analysis. World J Surg. 2016;40:2988–2998.
Arzu GD, De Ruvo N, Montalti R, et al. Temporary porto-caval shunt utility during orthotopic liver transplantation. Transplant Proc. 2008;40:1937–1940.
Nacif LS, Zanini LY, Costa Dos Santos JP, et al. Intraoperative temporary portocaval shunt in liver transplant. Transplant Proc. 2020;52:1314–1317.
Lapisatepun W, Lapisatepun W, Agopian V, et al. Venovenous bypass during liver transplantation: a new look at an old technique. Transplant Proc. 2020;52:905–909.
Reddy K, Mallett S, Peachey T. Venovenous bypass in orthotopic liver transplantation: time for a rethink? Liver Transpl. 2005;11:741–749.
Chari RS, Gan TJ, Robertson KM, et al. Venovenous bypass in adult orthotopic liver transplantation: routine or selective use? J Am Coll Surg. 1998;186:683–690.
Wall WJ, Grant DR, Duff JH, et al. Liver transplantation without venous bypass. Transplantation. 1987;43:56–61.
Fan ST, Yong BH, Lo CM, et al. Right lobe living donor liver transplantation with or without venovenous bypass. Br J Surg. 2003;90:48–56.
Johnson MW, Powelson JA, Auchincloss H Jr, et al. Selective use of veno-venous bypass in orthotopic liver transplantation. Clin Transplant. 1996;10:181–185.
Stegall MD, Mandell S, Karrer F, et al. Liver transplantation without venovenous bypass. Transplant Proc. 1995;27:1254–1255.
Leithead JA, Tariciotti L, Gunson B, et al. Donation after cardiac death liver transplant recipients have an increased frequency of acute kidney injury. Am J Transplant. 2012;12:965–975.
Leithead JA, Rajoriya N, Gunson BK, et al. The evolving use of higher risk grafts is associated with an increased incidence of acute kidney injury after liver transplantation. J Hepatol. 2014;60:1180–1186.
Kiuchi T, Kasahara M, Uryuhara K, et al. Impact of graft size mismatching on graft prognosis in liver transplantation from living donors. Transplantation. 1999;67:321–327.
Reddy MS, Kaliamoorthy I, Rajakumar A, et al. Double-blind randomized controlled trial of the routine perioperative use of terlipressin in adult living donor liver transplantation. Liver Transpl. 2017;23:1007–1014.
Sahmeddini MA, Amini A, Naderi N. The effect of octreotide on urine output during orthotopic liver transplantation and early postoperative renal function: a randomized, double-blind, placebo-controlled trial. Hepat Mon. 2013;13:e12787.
Fondevila C, Hessheimer AJ, Taurá P, et al. Portal hyperperfusion: mechanism of injury and stimulus for regeneration in porcine small-for-size transplantation. Liver Transpl. 2010;16:364–374.
Fahrner R, Patsenker E, de Gottardi A, et al. Elevated liver regeneration in response to pharmacological reduction of elevated portal venous pressure by terlipressin after partial hepatectomy. Transplantation. 2014;97:892–900.
Du Z, Zhou Y, Lu X, et al. Octreotide prevents liver failure through upregulating 5’-methylthioadenosine in extended hepatectomized rats. Liver Int. 2016;36:212–222.
Kohler A, Perrodin S, De Gottardi A, et al. Effectiveness of terlipressin for prevention of complications after major liver resection—a randomized placebo-controlled trial. HPB (Oxford). 2020;22:884–891.